Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidence

Autor: G. Karen Yu, Mika Aoyagi-Scharber, Jonathan H. LeBowitz, Wyatt T. Clark
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Models
Molecular

Epidemiology
Protein Conformation
lcsh:Medicine
Disease
medicine.disease_cause
Pathology and Laboratory Medicine
Geographical Locations
Mucopolysaccharidosis III
Medicine and Health Sciences
Missense mutation
Exome
lcsh:Science
Exome sequencing
Genetics
Mutation
Multidisciplinary
Approximation Methods
Incidence (epidemiology)
Incidence
Europe
Bioassays and Physiological Analysis
Deletion Mutation
Physical Sciences
Pathogens
Statistics (Mathematics)
Research Article
Mutation
Missense

Biology
Research and Analysis Methods
03 medical and health sciences
Unknown Significance
Genetic variation
Acetylglucosaminidase
medicine
Confidence Intervals
Humans
Allele
Allele frequency
Gene
Alleles
Enzyme Assays
lcsh:R
Biology and Life Sciences
Genetic Variation
030104 developmental biology
Genetic Loci
People and Places
lcsh:Q
Biochemical Analysis
Mathematics
Zdroj: PLoS ONE
PLoS ONE, Vol 13, Iss 7, p e0200008 (2018)
ISSN: 1932-6203
Popis: Given the large and expanding quantity of publicly available sequencing data, it should be possible to extract incidence information for monogenic diseases from allele frequencies, provided one knows which mutations are causal. We tested this idea on a rare, monogenic, lysosomal storage disorder, Sanfilippo Type B (Mucopolysaccharidosis type IIIB).Sanfilippo Type B is caused by mutations in the gene encoding α-N-acetylglucosaminidase (NAGLU). There were 189 NAGLU missense variants found in the ExAC dataset that comprises roughly 60,000 individual exomes. Only 24 of the 189 missense variants were known to be pathogenic; the remaining 165 variants were of unknown significance (VUS), and their potential contribution to disease is unknown.To address this problem, we measured enzymatic activities of 164 NAGLU missense VUS in the ExAC dataset and developed a statistical framework for estimating disease incidence with associated confidence intervals. We found that 25% of VUS decreased the activity of NAGLU to levels consistent with Sanfilippo Type B pathogenic alleles. We found that a substantial fraction of Sanfilippo Type B incidence (67%) could be accounted for by novel mutations not previously identified in patients, illustrating the utility of combining functional activity data for VUS with population-wide allele frequency data in estimating disease incidence.
Databáze: OpenAIRE